Surface-Enhanced Raman Scattering Imaging of Dynamic pH Changes in Lysosomes during Cancer Cell Invasion on a Microfluidic Chip by Sijia Liu (1751842)

Characteristics of EF1-driven single copy NR1I2, NR4A1, or RORA stably-transfected cells. by Yoshinori Hasegawa (308240)

Non-normalized data using variance and covariance, using the full set of 352 subjects. by Takuya Ito (57473)

Schematic diagram for the association between different clinical laboratory data and CT severity score in COVID-19 patients. by Ahmed Ismail (2671822)

Data.Rda for How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime... by Benjamin Kearns (2758267)

Evaluating the Potential of Ozone Microbubbles for Inactivation of Tulane Virus, a Human Norovirus Surrogate by Bozhong Guan (18598178)

“…After 2, 10, and 20 min postgeneration, the ozone concentration of microbubbles naturally decreased from 4 ppm to 3.2 ± 0.2, 2.26 ± 0.19, and 1.49 ± 0.23 ppm and resulted in 1.43 ± 0.44, 0.88 ± 0.5, and 0.68 ± 0.53 log₁₀ viral reductions, respectively, while the ozone concentration of aqueous ozone decreased from 4 ppm to 2.52 ± 0.07, 0.43 ± 0.05, and 0.09 ± 0.01 ppm and produced 0.8 ± 0.28, 0.29 ± 0.41, and 0.16 ± 0.21 log₁₀ reductions against Tulane virus, respectively (<i>p</i> = 0.0526), suggesting that structuring of ozone in the bubbles over the applied treatment conditions did not have a significant effect, though future study with continuous generation of ozone microbubbles is needed.…”

A shows the week of vehicle/dFBr injections dFBr in the IA2BC timeline followed by 1 week post-treatment washout period. by Steven Decker (13767223)

“…E. dFBr significantly decreases voluntary 20% ethanol consumption at the 4 hr time-point in female SD rats (n = 12/group). …”

Association between blood pressure and the probability of falls (n = 2249). by David Röthlisberger (17684467)

Correlation between clinical laboratory data and CT severity score in COVID-19 patients at Fayoum University Hospital in Egypt. by Ahmed Ismail (2671822)

Descriptive statistics of HIV care and treatment outcomes in the D.C. DOC per month. by Samantha R. Levano (16437504)

Total number of entrants and rate of HIV testing and results received, Washington D.C. by Samantha R. Levano (16437504)

A visual summary of the key study findings. by Joachim Worthington (8394213)

“…Modelling was used to estimate short- and long-term effects on colorectal cancer incidence and mortality, including ongoing impact of patient backlogs. A hypothetical mitigation strategy was simulated, with diagnostic and treatment capacities increased by 5% from 2022 to address backlogs. …”

Table_5_A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardi... by Alexandra Gomes dos Santos (9449003)

Phenotypic and physiological assessment of DP and IR28 seedlings under control and salt stress conditions. by Duc Quan Nguyen (8570142)

Association between blood pressure and the probability of falls in participants with and without antihypertensives (without antihypertensives: n = 890 no antihypertensives; with an... by David Röthlisberger (17684467)

SURF6 overexpression does not disturb morphology of HeLa cells [31]. by Anastasiia Moraleva (16548419)

Association between blood pressure and the probability of falls in participants with and without cardiovascular disease (CVD) (without CVD: n = 1300; with CVD: n = 938). by David Röthlisberger (17684467)

Level and trend changes in predicted rates^a in HIV care and treatment. by Samantha R. Levano (16437504)

SURF6 knockdown does not disturb morphology of HeLa cells. by Anastasiia Moraleva (16548419)

Persistent HIV-1 suppression after deferiprone cessation in treatment-naive HIV-infected subjects. by Deepti Saxena (462177)

“…<p>Discontinuation trial design (DTD) is used to analyze long-term rebound following HIV-1 RNA—based segregation into a ‘Decrease’ and a ‘No decrease’ cohort, defined by viral load post-drug on Day 7 relative to viral load pre-drug on Day 1. …”